Home / Intelligence / Blog / AI-Based Software Paige Prostate is Granted FDA Approval Through the De Novo Regulatory Pathway
Published September 27, 2021
Paige Prostate is the first artificial intelligence (AI)-based software designed to identify areas of concern (i.e., high likelihood of containing cancer) on a prostate biopsy image so they can be flagged for further review by a pathologist. The program is intended to be used as an adjunct tool to the review of digital scanner slide images from prostate biopsies.
The program was reviewed through the De Novo pathway, a regulatory pathway for low-to-moderate risk novel devices. The FDA authorization is based on clinical trial data which suggests improved detection of cancer on slide images by an average of 7.3% with Paige Prostate vs. unassisted examination by pathologists. The program also reduced the number of false-negatives by 70% and false-positives by 24%. This FDA authorization follows Paige AI receiving a CE mark for both its prostate software and its breast cancer product for use in the EU last year.
Paige’s co-founder and chief medical officer, David Klimstra, notes that Paige’s landmark FDA-approval and EU access “marks the beginning of a new era in the use of computer-assisted diagnostics for pathology.”
Written by Crystal Zhao and Kate Watkins
Related Intelligence
Webinars
AI-Powered HCP Call Planning: A Case Study in Business Transformation
July 23, 2025 | 12:00 – 12:45 PM ET
Field sales teams are a vital link between life sciences companies and healthcare professionals (HCPs), with effective call planning critical for success. As companies embrace new technologies to enhance their selling processes, they often face challenges such as resistance to change, training needs and integrating systems with existing workflows. Join our panel discussion with Bausch […]
Sign Up Now
Blog
Empowering Field Teams: A Case Study in AI-Driven Call Planning
Field sales serve as the primary bridge between companies and healthcare professionals to build trust, provide valuable information and drive product adoption. Effective call planning is essential, as it allows reps to prioritize their engagements, tailor messaging and maximize their impact. The introduction of new technologies to streamline or enhance field operations comes with inherent […]
Read More
Blog
2025 Oncology Mid-Year Check-in: Reflections & Expectations
Reflecting on the first half of 2025 including data from AACR, ASCO and EHA, we see several notable trends continuing to shape the oncology landscape. While development follows momentum observed the last few years, these learnings provide a clearer understanding into the next wave of innovation. Immunotherapy Moves Earlier in the Journey One of the […]
Read More